Annexon Biosciences to Participate in 2021 Cantor Virtual Global Healthcare ConferenceGlobeNewsWire • 09/23/21
Annexon Biosciences to Highlight Neurodegeneration Franchise in Upcoming Virtual C1q Series R&D EventGlobeNewsWire • 09/20/21
Annexon Biosciences Reports Second Quarter 2021 Financial Results and Provides Mid-Year Business UpdateGlobeNewsWire • 08/16/21
Annexon Broadens Autoimmune Franchise with Advancement of Third Anti-C1q Product Candidate and Strategic Expansion into New Autoantibody-driven DiseasesGlobeNewsWire • 07/22/21
Annexon Biosciences Provides Business Update and Reports First Quarter 2021 Financial ResultsGlobeNewsWire • 05/17/21
Annexon Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results with Recent Business HighlightsGlobeNewsWire • 03/25/21
Annexon Shares Gain After Patient Dosing Starts In Mid-Stage Study For Vision Loss Disorder TherapyBenzinga • 03/01/21
Annexon Advances Classical Complement Platform with Initiation of Global Phase 2 ARCHER Trial in Patients with Geographic AtrophyGlobeNewsWire • 03/01/21
Annexon Highlights Recent Achievements and Outlines Expected Key Milestones in 2021 for Its Broad Portfolio of Complement TherapeuticsGlobeNewsWire • 01/12/21